Visceral Leishmaniasis and HIV Co-infection in Bihar, India: Long-term Effectiveness and Treatment Outcomes with Liposomal Amphotericin B (AmBisome).

Hdl Handle:
http://hdl.handle.net/10144/325190
Title:
Visceral Leishmaniasis and HIV Co-infection in Bihar, India: Long-term Effectiveness and Treatment Outcomes with Liposomal Amphotericin B (AmBisome).
Authors:
Burza, Sakib; Mahajan, Raman; Sinha, Prabhat K; van Griensven, Johan; Pandey, Krishna; Lima, María Angeles; Sanz, Marta Gonzalez; Sunyoto, Temmy; Kumar, Sunil; Mitra, Gaurab; Kumar, Ranjeet; Verma, Neena; Das, Pradeep
Journal:
PLoS Neglected Tropical Diseases
Abstract:
Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the Indian state of Bihar, while HIV/AIDS is an emerging disease in this region. A 2011 observational cohort study conducted in Bihar involving 55 VL/HIV co-infected patients treated with 20-25 mg/kg intravenous liposomal amphotericin B (AmBisome) estimated an 85.5% probability of survival and a 26.5% probability of VL relapse within 2 years. Here we report the long-term field outcomes of a larger cohort of co-infected patients treated with this regimen between 2007 and 2012.
Publisher:
PLoS
Issue Date:
7-Aug-2014
URI:
http://hdl.handle.net/10144/325190
DOI:
10.1371/journal.pntd.0003053
PubMed ID:
25101665
Language:
en
ISSN:
1935-2735
Appears in Collections:
Leishmaniasis/Kala Azar

Full metadata record

DC FieldValue Language
dc.contributor.authorBurza, Sakiben_GB
dc.contributor.authorMahajan, Ramanen_GB
dc.contributor.authorSinha, Prabhat Ken_GB
dc.contributor.authorvan Griensven, Johanen_GB
dc.contributor.authorPandey, Krishnaen_GB
dc.contributor.authorLima, María Angelesen_GB
dc.contributor.authorSanz, Marta Gonzalezen_GB
dc.contributor.authorSunyoto, Temmyen_GB
dc.contributor.authorKumar, Sunilen_GB
dc.contributor.authorMitra, Gauraben_GB
dc.contributor.authorKumar, Ranjeeten_GB
dc.contributor.authorVerma, Neenaen_GB
dc.contributor.authorDas, Pradeepen_GB
dc.date.accessioned2014-08-25T16:33:07Z-
dc.date.available2014-08-25T16:33:07Z-
dc.date.issued2014-08-07-
dc.identifier.citationVisceral Leishmaniasis and HIV Co-infection in Bihar, India: Long-term Effectiveness and Treatment Outcomes with Liposomal Amphotericin B (AmBisome). 2014, 8 (8):e3053 PLoS Negl Trop Disen_GB
dc.identifier.issn1935-2735-
dc.identifier.pmid25101665-
dc.identifier.doi10.1371/journal.pntd.0003053-
dc.identifier.urihttp://hdl.handle.net/10144/325190-
dc.description.abstractVisceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the Indian state of Bihar, while HIV/AIDS is an emerging disease in this region. A 2011 observational cohort study conducted in Bihar involving 55 VL/HIV co-infected patients treated with 20-25 mg/kg intravenous liposomal amphotericin B (AmBisome) estimated an 85.5% probability of survival and a 26.5% probability of VL relapse within 2 years. Here we report the long-term field outcomes of a larger cohort of co-infected patients treated with this regimen between 2007 and 2012.en_GB
dc.language.isoenen
dc.publisherPLoSen_GB
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseasesen_GB
dc.titleVisceral Leishmaniasis and HIV Co-infection in Bihar, India: Long-term Effectiveness and Treatment Outcomes with Liposomal Amphotericin B (AmBisome).en
dc.identifier.journalPLoS Neglected Tropical Diseasesen_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.